- Home
- KNOP vs PLX Comparison
KNOP vs PLX Comparison
Compare KNOP & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- PLX
- Stock Information
- Founded
- KNOP 2013
- PLX 1993
- Country
- KNOP United Kingdom
- PLX Israel
- Employees
- KNOP N/A
- PLX N/A
- Industry
- KNOP Marine Transportation
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNOP Consumer Discretionary
- PLX Health Care
- Exchange
- KNOP Nasdaq
- PLX Nasdaq
- Market Cap
- KNOP 199.5M
- PLX 160.2M
- IPO Year
- KNOP 2013
- PLX 1998
- Fundamental
- Price
- KNOP $7.62
- PLX $2.56
- Analyst Decision
- KNOP
- PLX Strong Buy
- Analyst Count
- KNOP 0
- PLX 1
- Target Price
- KNOP N/A
- PLX $15.00
- AVG Volume (30 Days)
- KNOP 91.4K
- PLX 741.9K
- Earning Date
- KNOP 03-19-2025
- PLX 03-17-2025
- Dividend Yield
- KNOP 1.36%
- PLX N/A
- EPS Growth
- KNOP N/A
- PLX N/A
- EPS
- KNOP 0.18
- PLX 0.04
- Revenue
- KNOP $312,629,000.00
- PLX $53,399,000.00
- Revenue This Year
- KNOP $1.40
- PLX $67.17
- Revenue Next Year
- KNOP $2.53
- PLX $55.31
- P/E Ratio
- KNOP $37.75
- PLX $69.84
- Revenue Growth
- KNOP 8.60
- PLX N/A
- 52 Week Low
- KNOP $4.94
- PLX $0.82
- 52 Week High
- KNOP $9.11
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- KNOP 81.62
- PLX 57.87
- Support Level
- KNOP $6.53
- PLX $2.43
- Resistance Level
- KNOP $6.84
- PLX $2.62
- Average True Range (ATR)
- KNOP 0.25
- PLX 0.15
- MACD
- KNOP 0.17
- PLX 0.02
- Stochastic Oscillator
- KNOP 95.77
- PLX 80.75
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.